Sun Pharma




Concise Prescribing Info
Alfuzosin HCl
Functional symptomatic treatment of benign prostatic hypertrophy. Adjunctive treatment for vesical catheterization in acute urinary retention associated w/ benign prostatic hypertrophy.
Dosage/Direction for Use
1 tab daily after evening meal. Adjunctive treatment following vesical catheter insertion in acute urinary retention associated w/ benign prostatic hypertrophy 1 tab daily after meal for 3-4 days (w/ 2-3 days during catheterization & 1 day following its removal). Start treatment on the day of urethral catheter insertion.
Should be taken with food: Take immediately after evening meal. Swallow whole w/ glass of water, do not crunch/chew/crush/ground into powd.
Hypersensitivity. Postural hypotension. Concomitant use w/ other α1-blockers & potent CYP3A4 inhibitors. Hepatic insufficiency. Severe kidney failure (CrCl <30 mL/min).
Special Precautions
Discontinue treatment if angina pectoris recurs or worsens. Postural hypotension may occur; hypotension in elderly. Patients w/ symptomatic orthostatic hypotension; acquired or congenital QT prolongation; coronary disease. Priapism; intraoperative floppy iris syndrome. Inform ophth surgeons in advance of cataract surgery of current or past use of α 1-blockers. Sugar intolerance. Concomitant use w/ antihypertensives or nitrates; QT-prolonging medications. Postural hypotension, vertigo, dizzy sensations, asthenia, visual disturbances that may affect ability to drive & use machines. Pregnancy & lactation. Childn 2-16 yr. Elderly.
Adverse Reactions
Faintness/dizziness, headache; nausea, abdominal pain, vomiting; asthenia.
Drug Interactions
Enhanced hypotensive effect w/ α1-receptor blockers (prazosin, urapidil, minoxidil). Increased blood levels w/ potent CYP3A4 inhibitors eg, ketoconazole, itraconazole, clarithromycin, erythromycin & ritonavir. Enhanced antihypertensive effect & increased risk of postural hypotension w/ antihypertensives. Concomitant use w/ nitrates.
MIMS Class
Drugs for Bladder & Prostate Disorders
ATC Classification
G04CA01 - alfuzosin ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.
Flotral PR tab 10 mg
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in